# A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

> **NCT02768207** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT02768207
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-23
- **Primary completion:** 2017-12-20
- **Final completion:** 2019-06-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768207, "A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02768207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*